Literature DB >> 25840747

Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.

Umberto Gianelli1, Alessandra Iurlo2, Daniele Cattaneo3, Anna Bossi4, Ivan Cortinovis5, Claudia Augello6, Alessia Moro7, Federica Savi8, Roberto Castelli9, Cecilia Brambilla10, Paola Bianchi11, Massimo Primignani12, Agostino Cortelezzi13, Silvano Bosari14.   

Abstract

We examined a consecutive series of 29 patients with myeloproliferative neoplasms (MPNs) associated with splanchnic vein thrombosis (SVT) in order to evaluate their bone marrow morphology and identify possible associations between histological findings and clinical features. Eleven patients showed the morphological features of polycythemia vera (PV), 11 of primary myelofibrosis (PMF) and six of essential thrombocythemia (ET). Molecular analyses identified the JAK2 V617F mutation in 27 patients; one of the JAK2-negative patients carried the MPL W515K mutation, the other was "triple-negative" (no JAK2, MPL or CALR mutation). On the basis of the WHO classification, three patients were classified as having PV, 11 as having PMF, and two as having ET; the remaining 13 cases fell into the MPN-unclassifiable category as there were discrepancies between their morphological and clinical features. In conclusion, our findings suggest that bone marrow histology should always be considered a key component of the diagnostic algorithm in patients with SVT, but that it is not enough to distinguish the different entities. This is particularly important because diagnoses of PV, PMF or ET have very different prognoses and obviously imply different therapies. It is therefore necessary to adopt a comprehensive approach that considers morphological, clinical and molecular data.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow morphology; Essential thrombocythemia; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis; Splanchnic vein thrombosis

Mesh:

Substances:

Year:  2015        PMID: 25840747     DOI: 10.1016/j.leukres.2015.03.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Authors:  Umberto Gianelli; Daniele Cattaneo; Anna Bossi; Ivan Cortinovis; Leonardo Boiocchi; Yen-Chun Liu; Claudia Augello; Arturo Bonometti; Stefano Fiori; Nicola Orofino; Francesca Guidotti; Attilio Orazi; Alessandra Iurlo
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

Review 2.  Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms.

Authors:  Imo J Akpan; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 3.  Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037

4.  Tropical Fever: Unveiling an Asymptomatic Case of Polycythemia Vera.

Authors:  B Kishansing Naik; Sulakshana Sulakshana; Justin Aryabhat Gopaldas; Sai Devvrat
Journal:  Indian J Crit Care Med       Date:  2022-03

5.  High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.

Authors:  Roberto Castelli; Paolo Gallipoli; Riccardo Schiavon; Thomas Teatini; Giorgio Lambertenghi Deliliers; Luigi Bergamaschini
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.